It has been demonstrated that CRISPR-induced inhibition of PARP1 synergizes cisplatin cytotoxicity in ovarian cancer [22], which may lead to a potential concurrent platinum and PARP inhibition, instead of using small molecule inhibitors. The gene discussed is PARP1; the disease is ovarian carcinoma.